



MAJOR MILESTONE: U.S. Life Sciences Investments Top \$500B+

Pharmaceutical companies are continuing to invest big in America, **pledging more than \$582 billion** since 2025. The surge in American-based investment strengthens the future discovery and delivery of life-altering treatment for U.S. patients while benefiting a sector of the economy that America must continue to secure its position in as a world leader. The life science industry supports **more than 4.9 million jobs**, including **356K+ in New Jersey** as of 2022.

IN NEW JERSEY



At least four projects: **Merck's** \$3.5 billion headquarters upgrade in Rahway; **Roche's** expansion of existing sites; **Novartis's** manufacturing facility expansion in Millburn; and **Hikma's** expansion of generic manufacturing capabilities in Cherry Hill and Dayton



Congress: Protect America's Position As the World Leader in Life Sciences. Oppose Importing Foreign Healthcare Policies & MFN Drug Pricing

Continued sector investment requires a policy environment that encourages innovation and protects American jobs. Global competitors, including China, are closing the gap.

Drug pricing policies like Most Favored Nation threaten America's biotech revolution.

230+

fewer new
medicines
over 10 years

**1.1
million**

lost jobs

Surrender
competitive
edge to

China

Fail

to lower patient costs or
address the real drivers
of rising healthcare costs



Stay up-to-date on the latest life sciences' investment announcements and state-specific industry impact at www.workforhealth.org/investinamerica and www.workforhealth.org/in-the-states.

LEARN MORE AT WEWORKFORHEALTH.ORG